uniQure (NASDAQ:QURE) Raised to Sell at StockNews.com

uniQure (NASDAQ:QURE) was upgraded by StockNews.com to a “sell” rating in a research note issued to investors on Wednesday.

Several other analysts have also commented on QURE. Cantor Fitzgerald lifted their price objective on shares of uniQure from $28.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday. Royal Bank of Canada lowered their price target on shares of uniQure from $16.00 to $14.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of uniQure in a report on Tuesday. Raymond James upgraded uniQure from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $20.00 to $52.00 in a research note on Tuesday. Finally, The Goldman Sachs Group cut their price target on uniQure from $10.00 to $9.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $32.14.

uniQure Stock Performance

Shares of QURE opened at $15.06 on Wednesday. The stock has a 50 day moving average of $6.85 and a 200 day moving average of $6.28. The company has a market capitalization of $734.07 million, a price-to-earnings ratio of -3.04 and a beta of 0.89. uniQure has a 12 month low of $3.73 and a 12 month high of $17.39. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92.

uniQure (NASDAQ:QURE) last announced its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.12) by $0.21. The firm had revenue of $2.29 million during the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative return on equity of 188.82% and a negative net margin of 837.80%. As a group, sell-side analysts forecast that uniQure will post -3.74 earnings per share for the current year.

Insider Activity at uniQure

In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The shares were sold at an average price of $7.63, for a total transaction of $26,079.34. Following the completion of the transaction, the chief executive officer now owns 597,915 shares of the company’s stock, valued at approximately $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.74% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. RTW Investments LP bought a new position in shares of uniQure in the third quarter worth $49,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new stake in shares of uniQure during the 3rd quarter valued at about $53,000. Quarry LP bought a new stake in shares of uniQure during the 3rd quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its holdings in shares of uniQure by 21.0% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.